Table 1.
Input data and model results of the base case analysis of the 9-valent HPV vaccine and the exploratory analyses of the bivalent and quadrivalent HPV vaccines
| Input data | ||
| Parameter | Value | Reference/source |
| Vaccination age | 16 years | NA |
| Percentage of cervical cancer in China attributable to types 16/18/31/33/45/52/58 | 92.0% | 13 |
| Percentage of cervical cancer in China attributable to types 16/18 | 69.1% | 13 |
| 9-valent vaccine price for full doses (2017 US$) | $610 | 15 16 |
| Quadrivalent vaccine price for full doses (2017 US$) | $375 | 15 16 |
| Bivalent vaccine price for full doses (2017 US$) | $273 | 15 16 |
| Vaccine administration costs (2017 US$) | $18 | Model default with inflation adjustment16 18 |
| Cancer treatment costs (2017 US$) | $7183 | 18 19 |
| Efficacy of vaccine | 100% | Model default |
| Discount rate | 3% | Base case assumption |
| Disutility weight of cancer diagnosis | 0.08 | Model default |
| Disutility weight of non-terminal cancer sequelae | 0.11 | Model default |
| Disutility weight of terminal cancer | 0.78 | Model default |
DALY, disability-adjusted life year;HPV, human papillomavirus; ICER, incremental cost-effectiveness ratio measured as incremental costs per DALY prevented; NA, not applicable.